Abstract
Based on the results of an international multicenter randomized double-blind study III. phase, there was a 28% reduction in the risk of death in patients treated with cabazitaxel, with a median survival of 15.1 months compared to 12.7 months with mitoxantrone. Cabazitaxel slowed the progression of the disease, with a median progression-free survival (PFS) of 2.8 months compared with 1.4 months with mitoxantrone.